TAMSULOSIN HYDROCHLORIDE
Clinical safety rating: safe
Animal studies have demonstrated safety
Selective antagonist of alpha-1A and alpha-1D adrenergic receptors in the prostate, bladder neck, and prostatic urethra, causing smooth muscle relaxation and improved urine flow.
| Metabolism | Primarily hepatic via CYP3A4 and CYP2D6; metabolites undergo conjugation. |
| Excretion | Primarily hepatic metabolism (CYP3A4 and CYP2D6) followed by renal excretion. Approximately 75-90% of a dose is excreted in urine as inactive metabolites, with <10% as unchanged drug. Fecal excretion accounts for 10-15%. |
| Half-life | 9-13 hours in healthy subjects, but can increase to 14-16 hours in elderly patients. This supports once-daily dosing, though steady-state is reached by day 5. |
| Protein binding | 94-99% bound to plasma proteins, primarily alpha-1 acid glycoprotein (AAG). Binding is concentration-independent. |
| Volume of Distribution | 0.74 L/kg, indicating moderate distribution into extravascular tissues. |
| Bioavailability | Approximately 100% (oral) due to high absorption and minimal first-pass metabolism. Food reduces absorption rate but not extent; AUC is unchanged. |
| Onset of Action | Oral: 1-2 hours for improvement in urinary symptoms; maximal effect within 4-6 weeks. |
| Duration of Action | Therapeutic effects persist for 24 hours with once-daily dosing, allowing continuous symptom control. |
0.4 mg orally once daily, approximately 30 minutes after the same meal each day. For patients who fail to respond to 0.4 mg after 2-4 weeks, dose may be increased to 0.8 mg once daily.
| Dosage form | CAPSULE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl ≥10 mL/min). Not recommended for use in severe renal impairment (CrCl <10 mL/min) due to lack of data. |
| Liver impairment | No dose adjustment for mild hepatic impairment (Child-Pugh A). Contraindicated in moderate to severe hepatic impairment (Child-Pugh B or C) due to increased exposure and risk of adverse effects. |
| Pediatric use | Not approved for use in pediatric patients. Safety and efficacy have not been established. |
| Geriatric use | No specific dose adjustment required; however, elderly patients may be more sensitive to hypotensive effects. Initiate at 0.4 mg once daily and titrate cautiously. Monitor blood pressure and renal function regularly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Other antihypertensive drugs can have additive effects Can cause retrograde ejaculation and orthostatic hypotension.
| Breastfeeding | Tamsulosin is excreted in human milk in low amounts. The milk-to-plasma (M/P) ratio is not available. A study in rats showed that tamsulosin is excreted in milk. In humans, caution is advised, and breastfeeding is not recommended during tamsulosin therapy due to the potential for adverse effects in the infant. The American Academy of Pediatrics considers tamsulosin to be compatible with breastfeeding, but alternative agents with more data are preferred. |
| Teratogenic Risk | Tamsulosin hydrochloride is a selective alpha-1a adrenergic receptor antagonist. According to FDA pregnancy category B, animal reproduction studies have not demonstrated a risk to the fetus. However, there are no adequate and well-controlled studies in pregnant women. During the first trimester, use is not recommended due to potential for maternal hypotension and reduced uteroplacental perfusion. In the second and third trimesters, the drug should be used only if the potential benefit justifies the potential risk to the fetus. There is no evidence of teratogenicity in humans, but limited data are available. |
■ FDA Black Box Warning
None
| Common Effects | Impotence Decreased libido Ejaculation disorder Orthostatic hypotension sudden lowering of blood pressure on standing Breast enlargement in male Breast tenderness in male |
| Serious Effects |
["Known hypersensitivity to tamsulosin or any component","Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole) in patients with moderate to severe hepatic impairment"]
| Precautions | ["Orthostatic hypotension (dizziness, syncope), especially with dose initiation or dose increase","Intraoperative floppy iris syndrome (IFIS) during cataract surgery","Priapism (rare, requires immediate medical attention)","Use with caution in patients with severe renal or hepatic impairment"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure for hypotension, especially at initiation of therapy. Assess for orthostatic hypotension, syncope, or dizziness. Monitor fetal heart rate and uterine tone during labor and delivery if used for preterm labor or urinary retention. Assess neonatal adaptation if used near term. No specific fetal monitoring required beyond routine antenatal care. |
| Fertility Effects | Tamsulosin has been associated with ejaculatory dysfunction, including retrograde ejaculation and decreased semen volume, which may impair male fertility. In animal studies, no adverse effects on fertility were observed at clinically relevant doses. In women, there is no known direct effect on fertility, but the drug is not indicated for use in women. Use in men for benign prostatic hyperplasia may reduce fertility due to ejaculatory disorders; reversible upon discontinuation. |